Base editing is unquestionably one of the most exciting recent technology innovations in the field of genome editing. The

Location:Home > About Us > Blogs >

Base editing is unquestionably one of the most exciting recent technology innovations in the field of genome editing. The




Base editing is unquestionably one of the most exciting recent technology innovations in the field of genome editing. The development of these base editors in the lab of David Liu (Broad Institute/HHMI) enables the substitution of specific bases in DNA (C to T and A to G) without cleaving both strands of the DNA, potentially offering more precision than traditional CRISPR methods. Our speaker for this webinar, Dr. Nicole Gaudelli, led the development of the original A base editor in the Liu lab in 2017 and is currently is spearheading the application of base editing across a range of medical conditions at Beam Therapeutics.


Investigators around the world have seized on these new tools and are pursuing myriad applications from basic research to therapeutics to agricultural biotechnology. Using directed evolution, researchers have also developed a new generation of editors with hundreds of times more activity than the original constructs. Recent results have demonstrated the exciting potential of base editors in animal models for diseases including heart disease and progeria.

During this presentation, which is part of TriLink BioTechnologies gene editing and cell therapy webinar series, Dr. Gaudelli will discuss how her group has transformed off-the-shelf base editors from a technology developed in academia to a promising therapeutic tool through engineering, screening, and directed evolution. Among the topics she will present are:

A brief history of the ABCs of base editing
Advances in base editing precision, activity, and safety
Technical challenges and research priorities
Therapeutically relevant application of base editing technologies

T cell engineering with adenine base editors, as well as gamma-globin upregulation



Ubigene Biosciences is co-founded by biological academics and elites from China, the United States, and France. We are located in Guangzhou Science City, which serves as a global center for high technology and innovation. Ubigene Biosciences has 1000㎡ office areas and laboratories, involving genome editing, cell biology technology, and zebrafish research. We provide products and services for plasmids, viruses, cells, and zebrafish. We aim to provide customers with better gene-editing tools for cell or animal research.

We developed CRISPR-U™ and CRISPR-B™(based on CRISPR/Cas9 technology) which is more efficient than general CRISPR/Cas9 in double-strand breaking, CRISPR-U™ and CRISPR-B™ can greatly improve the efficiency of homologous recombination, easily achieve knockout (KO), point mutation (PM) and knockin (KI) in vitro and in vivo. 

Genome Editing Platform
——Focusing on the Application of CRISPR-U™ and CRISPR-B™ Gene Editing Technology
1. Provides various types of gene-editing vectors for different species.
2. Provides different virus packaging services, including lentiviruses, adenoviruses and adeno-associated viruses.3. Provides high-quality services for gene knockout, point mutation and knockin cell lines

Cell Biology Platform
——Focusing on primary cell
1. Provides over 400 types of primary cells.
2. Provides culture strategies and related products for different cell types.3. Provides cell biology-related services such as cell isolation, extraction and validation.